| Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, ... Cancer immunology research 4 (2), 146-156, 2016 | 117 | 2016 |
| Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. K Broos, M Keyaerts, Q Lecocq, D Renmans, T Nguyen, D Escors, ... Oncotarget, 2017 | 110 | 2017 |
| The ReNAissanCe of mRNA-based cancer therapy S Van Lint, D Renmans, K Broos, H Dewitte, I Lentacker, C Heirman, ... Expert review of vaccines 14 (2), 235-251, 2015 | 96 | 2015 |
| Targeting the tumor microenvironment to enhance antitumor immune responses K Van der Jeught, L Bialkowski, L Daszkiewicz, K Broos, C Goyvaerts, ... Oncotarget 6 (3), 1359, 2015 | 95 | 2015 |
| Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model S Du Four, SK Maenhout, K De Pierre, D Renmans, SP Niclou, ... Oncoimmunology 4 (4), e998107, 2015 | 72 | 2015 |
| Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours L Bialkowski, A van Weijnen, K Van der Jeught, D Renmans, ... Scientific reports 6, 2016 | 70 | 2016 |
| Immune checkpoint blockade combined with IL‐6 and TGF‐β inhibition improves the therapeutic outcome of m RNA‐based immunotherapy L Bialkowski, K Van der Jeught, S Bevers, P Tjok Joe, D Renmans, ... International journal of cancer 143 (3), 686-698, 2018 | 36 | 2018 |
| STAT3 modulates β-cell cycling in injured mouse pancreas and protects against DNA damage. S De Groef, D Renmans, Y Cai, G Leuckx, S Roels, W Staels, G Gradwohl, ... Cell Death & Disease 7 (6), 2016 | 19 | 2016 |
| Adjuvant-Enhanced mRNA Vaccines L Bialkowski, K Van der Jeught, D Renmans, A van Weijnen, C Heirman, ... RNA Vaccines: Methods and Protocols, 179-191, 2017 | 8 | 2017 |
| Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016; 4 (2): 146–156. doi: 10.1158/2326-6066 S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, ... CIR-15-0163.[Abstract][CrossRef][Google Scholar], 0 | 4 | |
| Non-invasive imaging of mouse PD-L1 in syngeneic tumor models by using radiolabeled-nanobody tracers K Broos, D Renmans, Q Lecocq, G Raes, M Keyaerts, N Devoogdt, ... European Molecular Imaging Meeting, 2017 | | 2017 |
| Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging using nanobodies K Broos, Q Lecocq, D Renmans, G Raes, M Keyaerts, N Devoogdt, ... PhD Day, 2017 | | 2017 |
| Nanobody-mediated imaging of the immune checkpoint ligand PD-L1 K Broos, Q Lecocq, D Renmans, G Raes, M Keyaerts, N Devoogdt, ... BACR Conference, 2017 | | 2017 |
| Nanobody-mediated imaging and inhibition of the immune checkpoint ligand PD-L1 K Broos, D Renmans, Q Lecocq, G Raes, K Thielemans, M Keyaerts, ... | | 2016 |
| mRNA as a vector to locally deliver functional immune checkpoint-blocking nanobodies. D Renmans, K Broos, C Heirman, N Devoogdt, K Thielemans, K Breckpot | | 2016 |
| NICHE: Nanobody-mediated Immune CHEckpoint imaging and inhibition K Broos, D Renmans, N Devoogdt, M Keyaerts, C Heirman, K Thielemans, ... BMIC Congress 2015, 2015 | | 2015 |
| NARNIA: Nanobody-encoding RNA as Inhibitor of immune checkpoint: Opening the wardrobe to a whole new world of cancer immunotherapeutics D Renmans, K Broos, C Heirman, M Keyaerts, K Breckpot, K Thielemans IVth PhD day@ Jette, Vrije Universiteit Brussel, Belgium, 31 March 2015, 2015 | | 2015 |
| Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res.(2016) 4: 146–56. doi: 10.1158/2326-6066 S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn CIR-15-0163, 0 | | |
